Mathiesen, Caroline Benedicte Kjærulff3; Wandall, Hans H.2; Pedersen, Anders Elm2
1 Laborant- og Procesteknologuddannelserne, Det Sundhedsfaglige og Teknologiske Fakultet, Professionshøjskolen Metropol, University Colleges2 unknown3 Laborant- og Procesteknologuddannelserne, Det Sundhedsfaglige og Teknologiske Fakultet, Professionshøjskolen Metropol, University Colleges
MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.
Immunopharmacology and Immunotoxicology, 2013, Vol 35, Issue 6, p. 649-652
clinical assessment methods, lab technology and radiography; ADCC; antibody; immunotherapy; MUC1; NK cell